Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia

Author details

Lindsey Wu[1*], Julia Mwesigwa[2], Muna Affara[3], Mamadou Bah[2], Simon Correa[2], Tom Hall[4], James Beeson[5], Kevin K.A. Tetteh[1], Immo Kleinschmidt[6,7], Umberto D'Alessandro[2], Chris Drakeley[1]

***Corresponding author:** lindsey.wu@lshtm.ac.uk

1. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical Diseases, Department of Infection Biology. London WC1E 7HT, UK.
2. Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine. Fajara, The Gambia.
3. Bernhard Nocht Institute for Tropical Medicine (BNITM). Arusha, Tanzania.
4. St. George's University of London (SGUL). London, United Kingdom.
5. Burnet Institute. Melbourne, Australia.
6. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology. London WC1E 7HT, UK.
7. School of Pathology, Wits Institute for Malaria Research, Faculty of Health Science, University of Witwatersrand, South Africa.

Email addresses:

LW: lindsey.wu@lshtm.ac.uk

JM: julia.mwesigwa@lshtm.ac.uk

MA: affara@bnitm.de

MB: mmbah@mrc.gm

SC: scorea@mrc.gm

TH: thall@sgul.ac.uk

JB: beeson@burnet.edu.au

KKAT: kevin.tetteh@lshtm.ac.uk

IK: immo.kleinschmidt@lshtm.ac.uk

UD: umberto.dalessandro@lshtm.ac.uk

CD: chris.drakeley@lshtm.ac.uk

Keywords: malaria, serology, surveillance

Abstract

Background

As malaria transmission declines, sensitive diagnostics are needed to evaluate interventions and monitor transmission. Serological assays measuring malaria antibody responses offer a cost-effective detection method to supplement existing surveillance tools.

Methods

A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative regions in The Gambia. Serological analysis included samples from the West Coast Region at the start and end of the season (July and December 2013) and from the Upper River Region in July and December 2013, and April and December 2014. Antigen-specific antibody responses to seven *Plasmodium falciparum (P.falciparum)* antigens – Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030, EBA175 RIII-V, *Pf*MSP1$_{19}$, *Pf*AMA1 - were quantified using a multiplexed bead-based assay. The association between antibody responses and clinical and parasitological endpoints was estimated at the individual, household, and population level.

Results

Strong associations were observed between clinical malaria and concurrent sero-positivity to Etramp5.Ag1 (aOR 4.56 95%CI 2.94 – 7.06), *Pf*MSP1$_{19}$ (aOR 3.84 95%CI 2.41 – 6.04) and *Pf*AMA1 (aOR 2.18 95%CI 1.23 – 3.84), while asymptomatic infection was associated with sero-positivity to all antigens. Village-level sero-prevalence amongst children 2-10 years against Etramp5.Ag1, HSP40.Ag1, and *Pf*MSP1$_{19}$ showed the highest correlations with clinical and *P.falciparum* infection incidence rates. For all antigens, there was increased odds of asymptomatic *P.falciparum* infection in subjects residing in a compound with greater than 50% sero-prevalence, with a 2- to 3-fold increase in odds of infection associated with Etramp5.Ag1, GEXP18, Rh2.2030, *Pf*MSP1$_{19}$ and *Pf*AMA1. For individuals residing in sero-positive compounds, the odds of clinical malaria were reduced, suggesting a protective effect.

Conclusions

At low transmission, long-lived antibody responses could indicate foci of malaria transmission that have been ongoing for several seasons or years. In settings where sub-patent infections are prevalent and fluctuate below the detection limit of polymerase chain reaction (PCR), the presence of short-lived antibodies may indicate recent infectivity, particularly in the dry season when clinical cases are rare. Serological responses may reflect a persistent reservoir of infection, warranting community-targeted interventions if individuals are not clinically apparent but have the potential to transmit. Therefore, serological surveillance at both the individual and household level may be used to target interventions where there are foci of asymptomatically infected individuals.

70 **Background**

71 As malaria transmission declines, the prevalence of infection becomes increasingly heterogeneous
72 and focal. In low transmission settings, highly sensitive diagnostics are needed to measure subtle
73 changes in malaria incidence, evaluate the effectiveness of community-based interventions, and
74 monitor potential re-introduction after elimination. Evidence suggests that infections below the
75 detection limit of microscopy and rapid diagnostic tests (RDTs) contribute to on-going transmission,
76 but the magnitude of their public health importance is yet to be determined.[1–3] Nucleic acid
77 amplification tests (NAATs), such as ultrasensitive quantitative polymerase chain reaction (qPCR), can
78 detect less than 1 parasite per microlitre[4,5], but are still sensitive to fluctuations in parasite density
79 during the course of an infection.

80 Serological assays measuring antibody responses may be a more stable diagnostic alternative, offering
81 a cost-effective detection method to supplement existing surveillance tools. A number of studies in
82 The Gambia have observed spatiotemporal variations in antibody responses to malaria over time[6,7],
83 with similar observations in Tanzania[8], Equatorial Guinea[9], and South Africa[10]. Newly developed
84 serological markers of recent exposure to malaria may now be capable of measuring short-term
85 changes in malaria transmission over periods as short as 1-2 years. However, these markers require
86 validation with population-representative data from a range of endemic settings[11,12]. Longitudinal
87 cohort studies provide a unique opportunity for a multi-metric assessment of transmission dynamics
88 using clinical, parasitological, and serological endpoints. The aim is to understand the relative accuracy
89 of different diagnostics and their utility in epidemiological surveillance.

90 Using a suite of novel serological markers of malaria exposure, this study determines the correlation
91 of antibody responses with clinical and parasitological endpoints at the individual, household, and
92 population level in four villages in rural Gambia over two years, estimating the strength of association
93 between serological markers and gold standard metrics of malaria infection. These findings will
94 support the utility of serology in measuring recent malaria transmission and allow selection of markers

most suitable for use in future surveillance, particularly for reactive detection strategies in elimination settings.

Methods

Data and sampling

A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative regions - West Coast (WCR), North Bank (NBR), Lower River (LRR), Central River (CRR) and Upper River (URR) Regions. *Plasmodium falciparum* (*Pf)* prevalence measured by polymerase chain reaction (PCR) ranged from 2.27 to 19.60% in the Central River and Upper River Regions respectively (Figure 1). As described by Mwesigwa et al,[13] the study aim was to understand the dynamics of malaria infection and the impact of annual mass drug administration (MDA). Residents more than six months of age were enrolled in the study, and monthly surveys were conducted during malaria transmission season from June to December each year, as well as surveys in the dry season in April 2014, and prior to the implementation of MDA in May and June 2014 and 2015.

Individual finger prick blood samples were collected for haemoglobin estimation and on filter paper (Whatman 3 Corporation, Florham Park, NJ, USA) for molecular and serological analysis. Clinical malaria cases were identified by passive case detection (PCD) at health facilities or in villages by study nurses in individuals with history of fever in the previous 24 hours or axillary temperature ≥ 37.5^{o}C and a positive Rapid Diagnostic Test (RDT) result (Paracheck *Pf*, Orchid Biomedical System, India).

Serological analysis included all available samples from the West Coast Region in Besse and N'Demban villages from surveys conducted at the start of the transmission season in July 2013 (N=537) and at the end of the season in December 2013 (N=526). In the Upper River Region, analysis included all samples collected in Njaiyal and Madino Samako in July 2013 (N=779), December 2013 (N=632), April (dry season) 2014 (N=823), and December 2014 (N=757) (Figure 1, Table 1). These regions represent extremes of two transmission intensities, with months selected at the start and end of the

119 transmission season. Samples from clinical PCD cases were linked by study participant identification
120 code to samples from the same individuals collected during routine monthly surveys.

121 This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal
122 consent was first obtained at village sensitisation meetings, followed by individual written informed
123 consent for all participants. Parents/guardians provided written consent for children less than
124 17 years, and assent was obtained from children between 12 and 17 years.

125 **Laboratory procedures**

126 Antigen-specific antibody responses were quantified using the Luminex MAGPIX protocol described in
127 Wu et al 2019.[14] Plasma was eluted from 6mm dried blood spots (DBS) (4 µl whole blood equivalent)
128 and shaken overnight at room temperature in 200 µl of protein elution buffer containing phosphate
129 buffered saline (PBS) (pH 7.2), 0.05% sodium azide and 0.05% Tween-20, yielding an initial 1:50 sample
130 dilution. One day prior to assay processing, samples were diluted to a final 1:500 dilution using 10 µl
131 of the 1:50 pre-dilution sample and 90 µl of blocking Buffer B to prevent non-specific binding (1xPBS,
132 0.05% Tween, 0.5% bovine serum albumin (BSA), 0.02% sodium azide, 0.1% casein, 0.5% polyvinyl
133 alcohol (PVA), 0.5% polyvinyl pyrrolidone (PVP) and 1,500 µg/ml *E.coli* extract). Negative and positive
134 controls were also incubated one day prior in Buffer B, with negative controls prepared at a 1:500
135 dilution and Gambian pooled positive controls in a 6-point 5-fold serial dilution (1:10-1:31,250). The
136 positive control was based on a pool of 22 serum samples from malaria hyper-immune individuals in
137 The Gambia, and ten individual plasma samples from European malaria-naive adults were used as
138 negative controls.

139 Samples were prepared for diagnostic PCR as described by Mwesigwa et al 2017.[13] Briefly, DNA was
140 extracted from three 6-mm DBS using the automated QIAxtractor robot (Qiagen). Negative and
141 positive (3D7) controls were included to control for cross contamination and DNA extraction
142 efficiency, respectively. The DBS were lysed by incubation in tissue digest buffer at 60 °C for 1 hour
143 and digested eluates were applied onto capture plates, washed, and the DNA eluted into 80 µl. The

144 extracted DNA (4 µl) was used in a nested PCR, amplifying the multi-copy *Plasmodium* ribosomal RNA
145 gene sequences using genus and species specific primers.[15] All PCR products were run using the
146 QIAxcel capillary electrophoresis system (Qiagen), using the screening cartridge and 15-1,000 bp-
147 alignment marker. Results were exported and double scored using both the QIAxcel binary scoring
148 function and manually by visualization of the gel images and discrepancies were scored by a third
149 independent reader. All readers were blinded to participant survey data.

150 **Statistical analyses**

151 Data analysis was based on total immunoglobulin (IgG) levels to five antigens as potential markers of
152 sero-incidence[16] - early transcribed membrane protein 5 (Etramp5.Ag1), gametocyte export protein
153 18 (GEXP18), heat shock protein 40 (HSP40.Ag1), erythrocyte binding antigen 175 RIII-V (EBA175),
154 reticulocyte binding protein homologue 2 (Rh2.2030). Two antigens associated with long-lived
155 antibody response – *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region
156 (*Pf*MSP1$_{19}$) and *P.falciparum* apical membrane antigen 1 (*Pf*AMA1) – were included as a comparison,
157 both historically used to assess sero-conversion rates over time[8,9] and previously studied in The
158 Gambia[6,7]. For antigens associated with long-lived antibodies (*Pf*MSP1$_{19}$, *Pf*AMA1), a two-component
159 Gaussian mixture model was used to define distributions of negative and positive antibody levels,
160 expressed in units of median fluorescence intensity (MFI). Sero-positivity thresholds were defined as
161 the mean log MFI values plus two standards deviations of the negative distribution.[17] Mixture models
162 were estimated using the '*normalmixEM'* function in the *'mixtools'* package v1.0.4 in R version 3.6.1.
163 For antigens associated with shorter-lived antibodies where statistical evidence of a bimodal
164 distribution of antibody responses in the population was not strong - Etramp5.Ag1, GEXP18,
165 HSP40.Ag1, EBA175, Rh2.2030 - the sero-positivity threshold was defined by the mean log MFI plus
166 three standard deviations of 71 malaria-naïve European blood donors used as negative controls.

167 Individual-level association between antibody response and the concurrent odds of clinical malaria
168 (passively detected via the health facility or study nurses in the community) or asymptomatic

169 *P.falciparum* infection (actively detected using PCR from monthly survey samples) were assessed using
170 generalised estimating equations (GEE). Analysis was adjusted for age group (1-5 years, 6-15 years,
171 and greater than 15 years) and use of long-lasting insecticide treated nets (LLINs) in the last 24 hours
172 and allowed for clustering at the compound level, where compound is a collection of households
173 centrally located around a main residence. The magnitude of the association between antibody
174 response and odds of infection was evaluated for interaction with age group.

175 Using a GEE model, individual-level odds of clinical malaria or asymptomatic infection was assessed
176 for association with residence in the same compound as a sero-positive individual. Similarly, the
177 association between individual odds of infection and compound-level sero-prevalence (<50% or
178 >50%), was assessed using a mixed-effects generalised linear model adjusted for age group and LLIN
179 use, with random-effects at the compound-level. To ensure that estimates are not biased by the sero-
180 prevalence of small compounds, analysis was weighted by the number of individuals in the compound
181 (whose sero-status was assessed) and only included compounds with at least four individuals. Models
182 were fit using the 'geeM' and 'lme4' packages in R version 3.14.

183 Village-level sero-prevalence in July and December 2013 amongst children aged 2-10 years was
184 compared against all-age clinical and *P.falciparum* infection incidence rates from the same months,
185 the latter of which were previously reported by Mwesigwa et al[13]. Monthly clinical and *P.falciparum*
186 infection incidence rates were defined respectively as the number of new clinical cases or *P.falciparum*
187 infections (PCR-positive individuals who were PCR-negative in the previous monthly survey) divided
188 by total person-years at risk. This age range was selected to align with other routine surveillance
189 metrics such as annual parasite index (API) commonly using this age group as a sentinel population.
190 The strength of the relationship between village-level incidence rates and sero-prevalence for each
191 antigen was assessed using Pearson's correlation coefficient.

192 **Results**

193 **Village-level seroprevalence**

194 Data from 2,005 individuals were available for analysis of antibody responses from 5,581 samples
195 between June 2013 and December 2014 (Tables 1 and 2). The majority of subjects were female in both
196 the West Coast (55.0%) and the Upper River (54.3%) Regions, and higher LLIN use in the West Coast
197 (96.6%) compared to the Upper River Region (46.6%). In the West Coast Region, incidence of *P.*
198 *falciparum* was three times higher in December than at the start of the transmission season, and five
199 times higher in December in the Upper River Region (Table 3). Sero-prevalence amongst 2-10 years
200 olds in the West Coast Region ranged from 1.4% (95%CI 0.0 - 3.1) for Rh2.2030 in July 2013 (start of
201 the transmission season) and 13.7% (95%CI 8.9-18.5) for Etramp5.Ag1 in December 2013 (end of
202 transmission season). In the Upper River Region, sero-prevalence across all antigens was higher,
203 ranging from 5.1% (95%CI 2.5-7.7) for *Pf*MSP1$_{19}$ in July to 36.1% (95%CI 30.0-42.2) for GEXP18 in
204 December (Table 3). Sero-prevalence in this age group was highly correlated with both clinical malaria
205 and *P.falciparum* infection incidence rates (Figure 2, Table 4).

206 In both regions in July and December 2013, correlations between *P.falciparum* infection rate and sero-
207 prevalence were strongest for Etramp5.Ag1 (ρ=0.98), HSP40.Ag1 (ρ=0.99), and *Pf*MSP1$_{19}$ (ρ=0.99).
208 Incidence of clinical malaria had the strongest correlations with Etramp5.Ag1 (ρ=0.98), HSP40.Ag1
209 (ρ=0.95), and *Pf*MSP1$_{19}$ (ρ=0.97). Correlations with both clinical incidence and *P.falciparum* infection
210 rates remained high for Etramp5.Ag1 (ρ=0.98 and ρ=0.96, respectively) and *Pf*MSP1$_{19}$ (ρ=0.96 and
211 ρ=0.98, respectively), but slightly lower for HSP40.Ag1 (ρ=0.85 and ρ=0.81, for clinical incidence and
212 *P.falciparum* infection rates respectively), after excluding data from December 2013 from the Upper
213 River Region as a potential outlier. These correlations are based on few datapoints, with three
214 observations when excluding URR December 2013.

215 **Individual-level association between clinical malaria, asymptomatic *P.falciparum* infection and**
216 **concurrent sero-positivity**

217 The odds of clinical malaria were higher in individuals sero-positive to five (out of seven) of the
218 antigens analysed (Etramp5.Ag1, GEXP18, Rh2.2030, *Pf*MSP1$_{19}$and *Pf*AMA1) (Figure 3A, Table 5). After

219 adjusting for age and LLIN use, clinical malaria was associated with concurrent sero-positivity to three
220 antigens (Etramp5.Ag1, *Pf*MSP1$_{19}$and *Pf*AMA1), while odds of asymptomatic infection were strongly
221 associated with sero-positivity to all antigens. Amongst individuals sero-positive for Etramp5.Ag1,
222 there was increased odds of both clinical malaria (aOR 4.56, 95%CI 2.94 – 7.06, p<0.001) and
223 asymptomatic infection (aOR 3.36, 95%CI 2.75 – 4.11, p<0.001) (Table 5). Association with clinical
224 malaria was slightly lower in individuals sero-positive for *Pf*MSP1$_{19}$ (aOR 3.82, 95%CI 2.41 - 6.04,
225 p<0.001) and *Pf*AMA1 (aOR 2.18, 95%CI 1.23 - 3.84, p=0.007). Odds of asymptomatic infection in
226 individuals sero-positive to GEXP18 (aOR 3.10, 95%CI 2.50 – 3.85, p<0.001), Rh2.2030 (aOR 3.10,
227 95%CI 2.44 - 3.94, p<0.001) and *Pf*AMA1 (aOR 3.83, 95%CI 2.95 - 4.98, p<0.001) was similar to
228 Etramp5.Ag1.

229 **Individual-level odds of clinical malaria, asymptomatic infection when residing in compounds with**
230 **sero-positive individuals**

231 The odds of clinical malaria were reduced for individuals residing in the same compound with an
232 individual sero-positive to any of the seven antigens (Figure 3B, Table 6), from an 83% reduction if
233 residing in the same compound as an individual sero-positive for Etramp5.Ag1 (aOR 0.17, 95%CI 0.03-
234 0.84, p=0.03) to a 95% reduction if residing in the same compound as someone sero-positive for
235 *Pf*AMA1 (aOR 0.05, 95%CI 0.01 - 0.47, p=0.009). Conversely, the odds of asymptomatic infection were
236 positively associated with residing in the same compound as sero-positive individuals for five antigens
237 (Etramp5.Ag1, GEXP18, Rh2.2030, *Pf*MSP1$_{19,}$ and *Pf*AMA1). Adjusted odds of asymptomatic infection
238 was nearly 3-fold higher if residing with an individual sero-positive for Etramp5.Ag1 (aOR 2.95, 95%CI
239 1.66 - 5.24, p<0.001) and for GEXP18 (aOR 2.71, 95%CI 1.58 - 4.63, p<0.001). If residing in a compound
240 with individuals sero-positive to Rh2.2030, *Pf*MSP1$_{19}$ or *Pf*AMA1, the odds of asymptomatic infection
241 were all nearly twice as high as individuals living in compounds sero-negative to these antigens (Table
242 6).

243 **Association between individual-level clinical malaria, asymptomatic infection, and compound sero-**
244 **prevalence**

245 When stratifying by compound-level sero-prevalence, mean regression estimates found a reduced
246 odds of clinical malaria if residing in compound with sero-prevalence less than 50% for all antigens,
247 and an increased odds of clinical malaria in compounds with greater than 50% sero-prevalence for
248 four antigens (Etramp5.Ag1, GEXP18, HSP40.Ag1, and *Pf*MSP1$_{19}$) (Figure 4A, Supplementary File 2 -
249 Tables S3, S7, S11, S19, and S23). However, these results were not statistically significant. There was
250 strong statistical evidence for increasing odds of asymptomatic infection with increasing compound
251 sero-prevalence for two antigens (Etramp5.Ag1 and *Pf*MSP1$_{19}$) (Figure 4B, Supplementary File 2 -
252 Tables S4, S24), and weaker statistical evidence for increasing odds of asymptomatic infection for
253 HSP40.Ag1 and Rh2.2030 (Supplementary File 2 - Tables S14, S16).

254 Antigens most associated with increased odds of asymptomatic infection were Etramp5.Ag1, GEXP18
255 and *Pf*MSP1$_{19}$. For Etramp5.Ag1, aOR 2.61 (95%CI 1.53 - 4.45, p<0.001) in compounds with less than
256 50% sero-prevalence to an aOR 8.32 (95%CI 5.32 - 13.03, p<0.001) in compound sero-prevalence
257 greater than 50%, compared to sero-negative compounds (Supplementary File 2 - Table S4). For
258 GEXP18, aOR ranged from 2.97 (95%CI 1.47 - 5.99, p=0.002) to 8.80 (95%CI 3.50 - 22.12, p<0.001)
259 (Supplementary File 3 - Table S8). For *Pf*MSP1$_{19}$, aOR ranged from 2.18 (95%CI 1.33 - 3.60, p=0.002) to
260 aOR 9.06 (95%CI 5.16 - 15.89, p<0.001) (Supplementary File 2 - Table S24). For HSP40.Ag1, EBA175,
261 and *Pf*AMA1, statistically strong evidence for increased odds of asymptomatic infection was only
262 observed in compounds with greater than 50% sero-prevalence (Supplementary File 2 - Tables S12,
263 S20, S28).

264 The spatial distribution of infections at both the start and end of the transmission season (June – July
265 2013 vs August-December 2013) suggest that clinical and asymptomatic malaria are localised near
266 households with Etramp5.Ag1 sero-positive individuals (Figure 5). There are a number of Etramp5.Ag1
267 sero-positive households at both the start and during the wet season without concurrent clinical or

268 asymptomatic infections present. However, this is more pronounced for *Pf*AMA1, where sero-
269 positivity could reflect a longer history of exposure than Etramp5.Ag1 (Supplementary File 3 - Figure
270 S2). While there are a limited number of clinical cases between June and July 2013, from August to
271 December 2013, these cases occur in proximity to households with asymptomatic and Etramp5.Ag1
272 sero-positive individuals.

273 **Discussion**

274 We investigated the association between antibody responses and clinical and parasitological
275 endpoints at the individual, compound, and population level in The Gambia. At the individual level,
276 clinical malaria was highly correlated with concurrent sero-positivity to Etramp5.Ag1, *Pf*MSP1$_{19}$ and
277 *Pf*AMA1, while asymptomatic infection was correlated with sero-positivity to all antigens included in
278 this study. The strongest associations were with sero-positivity to Etramp5.Ag1 and *Pf*AMA1. Village-
279 level sero-prevalence amongst children 2-10 years against antigens Etramp5.Ag1, HSP40.Ag1, and
280 *Pf*MSP1$_{19}$ showed the highest correlations with clinical incidence and *Pf* infection rates.

281 At the compound level, individuals had increased odds of asymptomatic infection when residing in a
282 compound with greater than 50% sero-prevalence to all antigens, with the highest odds associated
283 with sero-prevalence to Etramp5.Ag1, GEXP18, and *Pf*MSP1$_{19}$. These results do not imply a causal
284 relationship between serological responses and clinical outcomes or asymptomatic infection, but
285 highlight that infected individuals tend to be concurrently sero-positive to most of the serological
286 markers assessed. There was strong evidence of reduced odds of clinical malaria for individuals
287 residing in the same compound as an individual sero-positive to any of the antigens, suggesting a
288 protective effect.

289 While *Pf*MSP1$_{19}$ and *Pf*AMA1 have been used extensively to measure medium and long-term trends
290 in transmission intensity, these markers may be less sensitive to changes in transmission at higher
291 endemicities or to smaller short-term fluctuations due to the rapid acquisition of antibodies and the
292 long half-life of sero-positivity for many blood-stage antigens.[18–21] Individuals with clinical malaria or

293 with long-lived antibody responses in low transmission regions of western Gambia could indicate foci
294 of malaria transmission that have been ongoing for several transmission seasons or years. In areas
295 where parasite density is low and often missed by RDTs and microscopy, using serological markers
296 could support targeted interventions to clear or eliminate these residual reservoirs of human
297 infection. Antigens in this study associated with shorter-lived sero-positivity (Etramp5.Ag1, GEXP18,
298 and HSP40.Ag1) were positively correlated with either clinical malaria and asymptomatic infection,
299 and sometimes both. These antigens have been relatively recently identified and shown to decrease
300 rapidly after infection in Ugandan children.[16] In settings where most infections are sub-patent and
301 fluctuate above or below the detection limit of PCR, detecting the short-lived antibody response in
302 individuals or households could imply recent infectivity, particularly in the dry season where clinical
303 cases are rare.

304 While factors such as the method for determining sero-positivity cut-off values could affect estimates
305 of sero-prevalence or the magnitude of association between endpoints,[22] the observations in this
306 study have important implications. In particular, there is a very consistent trend of compound sero-
307 positivity being a risk factor for asymptomatic infection in contrast to being protective against clinical
308 malaria. The complex dynamics between clinical and parasitic immunity are not explained through
309 epidemiological data alone as previous studies have observed lower PCR density in areas of higher
310 transmission intensity[31] . Fluctuations in sero-positivity levels may be a strong indicator of a persistent
311 human reservoir of infection, warranting community-targeted interventions if individuals remain
312 infected but are not clinically apparent and continue to transmit. Household serological status could
313 be used for targeting interventions where there are foci of asymptomatically infected individuals.

314 Immuno-epidemiological studies will be subject to variations in antigen-specific antibody dynamics,
315 as well as the immunogenicity of recombinant antigen constructs. Differences in sequence selection
316 and expression systems may result in recombinant proteins that differ slightly from natural epitope
317 morphology. It is unclear the degree to which these subtle variations affect the strength of antibody
318 detection between recombinant antigens. While this study focuses primarily on total IgG responses,

319 quantification of antibody levels using a combination of isotypes or subclasses may allow for improved
320 detection of sero-incidence. For example, IgG3 antibodies are thought to be thought to bind more
321 weakly than IgG1 and IgG3.[23] Current evidence on the associations of antigen-specific IgG subclasses
322 with both exposure and immunity to malaria is varied[24,25]. Antigens will fall along a continuum of
323 suitability as either biomarkers of acute infection to correlates of protective immunity[26], and these
324 subtleties need to be considered when selecting targets for surveillance. The assays used in this study
325 have allowed us to quantify antibody responses to specific antigens. Therefore, it will also be valuable
326 to investigate the optimal combinations of antigens associated with both short-lived and long-lived
327 antibody responses in surveillance, which could be more routinely used to account for the breadth
328 of antibody response between individuals in a population.[27–29] Variations such as this could also
329 potentially be overcome by the use of multiple variants or chimeric antigen constructs.[30]

330 Changing household sero-prevalence throughout the season may influence the precision of estimates,
331 which could be overcome with more frequent sampling of serological data, such as three-month
332 intervals depending on the decay rate of antigen-specific antibodies. Given that household sero-
333 prevalence may be a robust proxy for past malaria exposure and is simultaneously associated with
334 increased risk of asymptomatic infections and but reduced risk of clinical malaria (potentially due to
335 partial immunity), the biological relationship between household serological status and the risk of
336 clinical or parasitic infection could be further investigated through controlled observational cohort
337 studies.

338 These findings indicate that a number of new serological markers of malaria exposure could be useful
339 for epidemiological surveillance in highly seasonal malaria transmission areas. There is potential for
340 several of the antigenic targets explored to be used for population-wide screening, all of which have
341 also been optimised for use on a multiplexed bead-based platform in research settings. Further
342 translating this to a lateral flow device may offer opportunities for more widespread application if use-
343 cases can be well established.[32] In light of the strong association between serological status and
344 increased asymptomatic infection, serological platforms may have direct utility as a screening tool in

345 active or reactive case detection strategies, most of which have relied on clinical index cases
346 presenting at health facilities and have shown variability in effectiveness.[33] Future work can also aim
347 to develop standardised methods for characterising serological responses at the village or cluster level
348 or as part of randomised trials, while optimal sampling timeframes and sentinel populations can be
349 designed for use in routine surveillance.

350 **Conclusions**

351 As more countries move towards malaria elimination, including several in sub-Saharan Africa, sensitive
352 diagnostics will be needed to further understand the dynamics between the parasite, host, and vector
353 at very low levels of transmission. Integrating newly developed serology markers of recent exposure
354 into existing field diagnostics will become more important in estimating the human reservoir and
355 inform targeting of elimination approaches at very low levels of transmission.

356 **List of abbreviations**

357 aOR: Adjusted odds ratio
358 CI: Confidence interval
359 DBS: Dried blood spot
360 EBA175: Erythrocyte binding antigen 175
361 Etramp5.Ag1: Early transcribed membrane protein 5
362 GEE: Generalised estimating equations
363 GEXP18: Gametocyte export protein 18 (GEXP18)
364 HSP40.Ag1: Heat shock protein 40
365 IgG: Immunoglobulin
366 LLIN: Long-lasting insecticide treated net
367 MDA: Mass drug administration (MDA)
368 MFI: Median fluorescence intensity
369 PCD: Passive case detection
370 PCR: Polymerase chain reaction
371 *Pf, P.falciparum*: *Plasmodium falciparum*
372 *Pf*AMA1: *P.falciparum* apical membrane antigen 1

373 *Pf*MSP1$_{19}$: *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region

374 RDT: Rapid diagnostic test

375 Rh2.2030: Reticulocyte binding protein homologue 2

376 URR: Upper River Region, The Gambia

377 WCR: West Coast Region, The Gambia

378

379 **Declaration of interests**

380 **Ethics approval and consent to participate**

381 This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal
382 consent was first obtained at village sensitisation meetings, followed by individual written informed
383 consent for all participants. Parents/guardians provided written consent for children less than
384 17 years, and assent was obtained from children between 12 and 17 years.

385 **Availability of data and materials**

386 The datasets used and/or analysed during the current study are available from the corresponding
387 author on reasonable request.

388 **Competing interests**

389 All authors declare no competing interests.

390 **Funding**

391 This study was funded by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral
392 Training Programme studentship received by LW. The funders had no role in the design of the study,
393 collection, analysis, interpretation of data or writing of the manuscript.

394 **Author contributions**

395 LW designed and coordinated the study, supervised and performed serological lab work, analysed the
396 data, and wrote the manuscript. JM and MA supervised field data collection and laboratory work. SC

397 and MB conducted the serological assays. KKAT and JB produced the antigens. KKAT and TH developed
398 the serological assay. JM, MA, UD, IK, and CD advised on study design, interpretation of findings, and
399 reviewed the manuscript. All authors read and approved the final manuscript.

400

401 **References**

402 1. Okell, L. C. *et al.* Factors determining the occurrence of submicroscopic malaria infections and
403 their relevance for control. *Nat. Commun.* **3**, 1237 (2012).

404 2. Bousema, T., Okell, L., Felger, I. & Drakeley, C. Asymptomatic malaria infections: detectability,
405 transmissibility and public health relevance. *Nat. Rev. Microbiol.* **12**, 833–40 (2014).

406 3. Wu, L. *et al.* Comparison of diagnostics for the detection of asymptomatic Plasmodium
407 falciparum infections to inform control and elimination strategies. *Nature* **528**, S86-93 (2015).

408 4. Andrews, L. *et al.* Quantitative real-time polymerase chain reaction for malaria diagnosis and
409 its use in malaria vaccine clinical trials. *Am. J. Trop. Med. Hyg.* **73**, 191–8 (2005).

410 5. Rockett, R. J. *et al.* A real-time, quantitative PCR method using hydrolysis probes for the
411 monitoring of Plasmodium falciparum load in experimentally infected human volunteers.
412 *Malar. J.* **10**, 48 (2011).

413 6. Okebe, J. *et al.* School-Based Countrywide Seroprevalence Survey Reveals Spatial
414 Heterogeneity in Malaria Transmission in the Gambia. *PLoS One* **9**, e110926 (2014).

415 7. van den Hoogen, L. L. *et al.* Serology describes a profile of declining malaria transmission in
416 Farafenni, The Gambia. *Malar. J.* **14**, 416 (2015).

417 8. Drakeley, C. J. *et al.* Estimating medium- and long-term trends in malaria transmission by
418 using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5108–13
419 (2005).

420 9. Cook, J. *et al.* Serological markers suggest heterogeneity of effectiveness of malaria control

421 interventions on Bioko Island, equatorial Guinea. *PLoS One* **6**, e25137 (2011).

422 10. Biggs, J. *et al.* Serology reveals heterogeneity of Plasmodium falciparum transmission in
423 northeastern South Africa: implications for malaria elimination. *Malar. J.* **16**, 48 (2017).

424 11. Helb, D. A. *et al.* Novel serologic biomarkers provide accurate estimates of recent
425 Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U. S.*
426 *A.* **112**, E4438-47 (2015).

427 12. Kerkhof, K. *et al.* Serological markers to measure recent changes in malaria at population
428 level in Cambodia. *Malar. J.* **15**, 529 (2016).

429 13. Mwesigwa, J. *et al.* Residual malaria transmission dynamics varies across The Gambia despite
430 high coverage of control interventions. *PLoS One* **12**, e0187059 (2017).

431 14. Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse
432 Plasmodium falciparum antigens to assess changes in malaria transmission using sero-
433 epidemiology. *Wellcome Open Res.* **4**, 26 (2019).

434 15. Snounou, G. Genotyping of Plasmodium spp. Nested PCR. *Methods Mol. Med.* **72**, 103–116
435 (2002).

436 16. Helb, D. A. *et al.* Novel serologic biomarkers provide accurate estimates of recent
437 Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U. S.*
438 *A.* **112**, E4438-47 (2015).

439 17. Stewart, L. *et al.* Rapid assessment of malaria transmission using age-specific sero-conversion
440 rates. *PLoS One* **4**, e6083 (2009).

441 18. Drakeley, C. J. *et al.* Estimating medium- and long-term trends in malaria transmission by
442 using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5108–13
443 (2005).

444 19. Bruce-Chwatt, L. J., Draper, C. C. & Konfortion, P. Seroepidemiological evidence of eradication

445 of malaria from Mauritius. *Lancet (London, England)* **2**, 547–51 (1973).

446 20. Wong, J. *et al.* Serological markers for monitoring historical changes in malaria transmission
447 intensity in a highly endemic region of Western Kenya, 1994-2009. *Malar. J.* **13**, 451 (2014).

448 21. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of malaria
449 transmission intensity. *Sci. Rep.* **6**, 19472 (2016).

450 22. Irion, A., Beck, H. P. & Smith, T. Assessment of positivity in immuno-assays with variability in
451 background measurements: a new approach applied to the antibody response to Plasmodium
452 falciparum MSP2. *J. Immunol. Methods* **259**, 111–8 (2002).

453 23. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to
454 Effector Functions. *Front. Immunol.* **5**, (2014).

455 24. Dobaño, C. *et al.* Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175
456 are differentially associated with incidence of malaria in Mozambican children. *Clin. Vaccine*
457 *Immunol.* **19**, 157–66 (2012).

458 25. Tongren, J. E. *et al.* Target antigen, age, and duration of antigen exposure independently
459 regulate immunoglobulin G subclass switching in malaria. *Infect. Immun.* **74**, 257–64 (2006).

460 26. Stanisic, D. I. *et al.* Acquisition of antibodies against Plasmodium falciparum merozoites and
461 malaria immunity in young children and the influence of age, force of infection, and
462 magnitude of response. *Infect. Immun.* **83**, 646–60 (2015).

463 27. Takala, S. L. & Plowe, C. V. Genetic diversity and malaria vaccine design, testing and efficacy:
464 preventing and overcoming 'vaccine resistant malaria'. *Parasite Immunol.* **31**, 560–573
465 (2009).

466 28. Scherf, A., Lopez-Rubio, J. J. & Riviere, L. Antigenic Variation in *Plasmodium falciparum*. *Annu.*
467 *Rev. Microbiol.* **62**, 445–470 (2008).

468 29. Neafsey, D. E. *et al.* Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria

Vaccine. *N. Engl. J. Med.* **373**, 2025–2037 (2015).

30. Krishnarjuna, B. *et al.* Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2. *Sci. Rep.* **6**, 20613 (2016).

31. Mosha, J. F. *et al.* Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. *Malar. J.* **12**, 221 (2013).

32. Greenhouse, B. *et al.* Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination. *Gates Open Res.* **3**, 131 (2019).

33. Hsiang, M. S. *et al.* Active Case Finding for Malaria: A 3-Year National Evaluation of Optimal Approaches to Detect Infections and Hotspots Through Reactive Case Detection in the Low-transmission Setting of Eswatini. *Clin. Infect. Dis.* (2019). doi:10.1093/cid/ciz403

491 **Table 1. Serology sample size. Number of compounds and individuals by village and survey month.**

	Compounds	Individuals			
West Coast Region		**July 2013**	**December 2013**	**April 2014**	**December 2014**
Besse	69	401	388	-	-
N'Demban	24	136	138	-	-
Subtotal WCR	93	537	526	-	-
Upper River Region					
Njaiyal	28	382	181	298	286
Madina Samako	43	397	451	525	471
Subtotal URR	71	779	632	823	757
Total	164	1316	1158	823	757

492

493 **Table 2. Study subject characteristics by region and survey month, n (%) out of total individual in monthly**
494 **survey**

West Coast Region	**July 2013**	**December 2013**	**April 2014**	**December 2014**
Gender			-	-
Male	240 (46.3)	227 (45.0)		
Female	278 (53.7)	277 (55.0)	-	-
Age category				
<5 years	112 (21.5)	104 (20.5)	-	-
5 -15 years	188 (36.1)	195 (38.5)	-	-
>15 years	221 (42.4)	208 (41.0)	-	-
LLIN use 24hr	519 (96.6)	492 (94.3)	-	-
Upper River Region	**July 2013**	**December 2013**	**April 2014**	**December 2014**
Gender				
Male	371 (47.9)	287 (45.7)	401 (49.0)	359 (47.5)
Female	404 (52.1)	341 (54.3)	417 (51.0)	396 (52.5)
Age category				
<5 years	164 (21.5)	144 (23.3)	186 (23.0)	175 (23.6)
5 -15 years	260 (34.1)	234 (37.8)	304 (37.6)	258 (34.9)
>15 years	339 (44.4)	241 (38.9)	318 (39.4)	307 (41.5)
LLIN use 24hr	278 (46.6)	245 (41.7)	301 (43.8)	283 (46.2)

495

496

497

498

499

500

501

502

503

504

505

506 **Table 3. Regional sero-prevalence (ages 2-10 years) by antigen and all-age incidence rates for clinical malaria**
507 **and *Pf* infection.** Mean sero-prevalence (%) and incidence rates with 95%CI shown in parentheses.

	West Coast Region (WCR)		Upper River Region (URR)	
	July 2013	**December 2013**	**July 2013**	**December 2013**
Clinical incidence rate	0.08 (0.04 - 0.21)	0.14 (0.04 - 0.44)	0.13 (0.04 - 0.39)	0.21 (0.1 - 0.51)
***Pf* infection rate**	0.23 (0.13 - 0.39)	0.67 (0.40 - 1.13)	0.56 (0.42 - 0.74)	2.87 (2.36 - 3.50)
Sero-prevalence (ages 2-10 years)				
Etramp5.Ag1	4.8% (1.9 - 7.8)	13.7% (8.9 - 18.5)	8.7% (5.4 - 12.1)	33.6% (27.6 - 39.6)
GEXP18	12.6% (8.0 – 17.1)	12.7% (8.0 – 17.3)	25.1% (20.0 – 30.2)	36.1% (30.0 – 42.2)
HSP40.Ag1	6.3% (3.0 - 9.6)	6.1% (2.8 - 9.4)	8.4% (5.1 - 11.6)	24.1% (18.7 - 29.5)
Rh2.2030	1.4% (0.0 - 3.1)	1.0% (0.0 - 2.4)	9.8% (6.3 - 13.3)	25.3% (19.8 - 30.8)
EBA175	1.9% (0.1 - 3.8)	1.0% (0.0 - 2.4)	7.3% (4.2 - 10.3)	15.8% (11.2 - 20.4)
***Pf*MSP1$_{19}$**	3.4% (0.9 - 5.8)	8.1% (4.3 - 11.9)	5.1% (2.5 - 7.7)	22.0% (16.8 - 27.2)
***Pf*AMA1**	4.8% (1.9 - 7.8)	4.1% (1.3 - 6.8)	17.8% (13.3 - 22.3)	33.2% (27.2 - 39.1)

508

509 **Table 4. Pearson's correlation coefficients between regional sero-prevalence (ages 2-10 years) and all-age**
510 **incidence rates for clinical malaria and *Pf* infection.** Correlation estimates are based on data from the West
511 Coast Region (WCR) and Upper River Region (URR) in July and December 2013. Correlations excluding data from
512 URR December 2013 are shown in brackets.

	Pearson's correlation coefficient	
Antigen	**Sero-prevalence vs. Clinical incidence rate**	**Sero-prevalence vs. *Pf* infection incidence rate**
Etramp5.Ag1	0.98 [0.96]	0.98 [0.98]
GEXP18	0.90 [0.69]	0.84 [0.63]
HSP40.Ag1	0.95 [0.85]	0.99 [0.81]
EBA175	0.87 [0.40]	0.91 [0.32]
Rh2.2030	0.88 [0.39]	0.94 [0.31]
***Pf*MSP1$_{19}$**	0.97 [0.96]	0.99 [0.98]
***Pf*AMA1**	0.87 [0.48]	0.89 [0.40]

513

514

515

516

517

518

519

520 **Table 5. Odds of clinical malaria and asymptomatic infection by individual serological status, unadjusted and**
521 **adjusted for age group (<5 years, 5-15 years, and > 15 years) and LLIN use in the last 24 hours.**

Odds of clinical malaria or asymptomatic infection amongst sero-positive individuals, by antigen						
	Unadjusted			Adjusted		
	OR	95%CI	p-value	aOR	95%CI	p-value
Etramp5.Ag1						
Clinical malaria	5.50	3.33 - 9.07	<0.001	4.56	2.94 - 7.06	<0.001
Asymptomatic infection	3.24	2.67 – 3.94	<0.001	3.36	2.75 - 4.11	<0.001
GEXP18						
Clinical malaria	2.40	1.38 - 4.18	0.002	1.40	0.85 - 2.31	0.182
Asymptomatic infection	2.99	2.43 - 3.68	<0.001	3.10	2.50 - 3.85	<0.001
HSP40.Ag1						
Clinical malaria	1.63	0.91 - 2.90	0.099	0.97	0.58 - 1.61	0.903
Asymptomatic infection	2.57	2.11 - 3.13	<0.001	2.66	2.14 - 3.31	<0.001
Rh2.2030						
Clinical malaria	2.08	1.08 - 4.01	0.029	1.13	0.66 - 1.93	0.662
Asymptomatic infection	2.51	2.04 - 3.10	<0.001	3.10	2.44 - 3.94	<0.001
EBA175						
Clinical malaria	1.32	0.66 - 2.66	0.431	1.19	0.65 - 2.17	0.574
Asymptomatic infection	2.13	1.77 – 2.56	<0.001	2.68	2.09 - 3.94	<0.001
***Pf*MSP1$_{19}$**						
Clinical malaria	3.54	1.88 - 6.69	<0.001	3.82	2.41 - 6.04	<0.001
Asymptomatic infection	2.33	1.87 - 2.92	<0.001	2.50	1.93 - 3.24	<0.001
***Pf*AMA1**						
Clinical malaria	2.20	1.26 - 3.86	0.006	2.18	1.23 - 3.84	0.007
Asymptomatic infection	2.66	2.16 - 3.29	<0.001	3.83	2.95 - 4.98	<0.001

522
523
524
525
526
527
528
529
530
531
532

533 **Table 6. Odds of clinical malaria and asymptomatic *Pf* infection by compound serological status.** Estimates are
534 weighted by compound size and shown as unadjusted odds ratios (OR) and adjusted odds ratios (aOR) for age
535 group (<5 years, 5-15 years, and > 15 years).

Odds of clinical malaria or asymptomatic *Pf* infection for individuals residing in sero-positive compounds						
	Unadjusted			**Adjusted**		
	OR	**95%CI**	**p-value**	**aOR**	**95%CI**	**p-value**
Etramp5.Ag1						
Clinical malaria	0.18	0.03 - 1.00	0.050	0.17	0.03 - 0.84	0.030
Asymptomatic infection	2.91	1.66 - 5.12	<0.001	2.95	1.66 - 5.24	<0.001
GEXP18						
Clinical malaria	0.12	0.02 - 0.84	0.032	0.11	0.02 - 0.68	0.017
Asymptomatic infection	2.74	1.61 - 4.67	<0.001	2.71	1.58 - 4.63	<0.001
HSP40.Ag1						
Clinical malaria	0.13	0.02 - 0.76	0.023	0.12	0.02 - 0.66	0.015
Asymptomatic infection	1.35	0.78 - 2.34	0.281	1.42	0.81 - 2.48	0.226
Rh2.2030						
Clinical malaria	0.07	0.01 - 0.46	0.006	0.06	0.01 - 0.33	0.001
Asymptomatic infection	1.73	0.97 - 3.06	0.062	1.96	1.12 - 3.44	0.019
EBA175						
Clinical malaria	0.07	0.01 - 0.58	0.014	0.07	0.01 - 0.54	0.011
Asymptomatic infection	1.04	0.53 - 2.05	0.915	1.06	0.53 - 2.13	0.875
***Pf*MSP1$_{19}$**						
Clinical malaria	0.15	0.03 - 0.83	0.030	0.11	0.03 - 0.48	0.003
Asymptomatic infection	1.92	1.17 - 3.14	0.010	2.00	1.21 - 3.29	0.007
***Pf*AMA1**						
Clinical malaria	0.06	0.01 - 0.56	0.014	0.05	0.01 - 0.47	0.009
Asymptomatic infection	2.01	1.03 - 3.91	0.040	2.04	1.03 - 4.03	0.041

536

537

538

539

540

541

542

543

544 **Figures**



545

546 **Figure 1.** Map of Malaria Transmission Dynamics Study with regions and study villages by PCR prevalence.

547



548

549 **Figure 2. Pearson's correlation between regional sero-prevalence (ages 2-10 years) and all-age incidence rates**
550 **for clinical malaria and *Pf* infection**. Correlations between sero-prevalence and incidence rates for clinical
551 malaria (new clinical episodes divided by person-years at risk) in red and *Pf* infection (new PCR infections divided
552 by person-years at risk) In blue were based on data from the West Coast Region (WCR) and the Upper River
553 Region (URR) in July and December 2013. Correlations excluding data from URR December 2013 shown in
554 brackets.



Figure 3. Odds clinical malaria and asymptomatic infection by a) individual sero-positivity status b) residing in the same compound as a sero-positive individual. Analyses is adjusted for age group (<5 years, 5-15 years, and >15 years) and LLIN use in the last 24 hours and weighted by compound size.



Figure 4. Odds of clinical malaria by compound sero-prevalence (a) and odds of asymptomatic infection by compound sero-prevalence (b). Analyses is adjusted for age group (<5 years, 5-15 years, and >15 years) and LLIN use in the last 24 hours and weighted by compound size.



Figure 5. Household geolocation of Etramp5. Ag1 sero-positive, clinical malaria and *Pf* infections across four villages. Spatial distribution of infections shown for lower transmission (N'demban) and higher transmission (Besse) villages in the West Coast Region (WCR) and lower transmission (Njaiyal) and higher transmission (Madina Samako) villages in the Upper River Region (URR). Infections at the start of the wet season (June – July 2013) shown on the left and during the wet and transmission season (August – December 2013) on the right.

573 **Additional files**

574 **Supplementary 1. Sero-prevalence amongst individuals aged 2 - 10 year and prevalence of sero-**
575 **positive compounds.**

576 **Supplementary 2. Odds of clinical malaria and asymptomatic infection for sero-positive individuals**
577 **and individuals residing in sero-positive compounds.** Unadjusted and adjusted odds ratios for seven
578 malaria antigenic targets - Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030, EBA175, *Pf*MSP1$_{19}$, and
579 *Pf*AMA1

580 **Supplementary 3. Map of household geolocation of *Pf*AMA1 sero-positive, clinical malaria and *Pf***
581 **infections across four villages during dry and wet transmission seasons.** Spatial distribution of
582 infections shown for lower transmission (N'demban) and higher transmission (Besse) villages in the
583 West Coast Region (WCR) and lower transmission (Njaiyal) and higher transmission (Madina Samako)
584 villages in the Upper River Region (URR). Infections at the start of the wet season (June – July 2013)
585 shown on the left and during the wet and transmission season (August – December 2013) on the right.

586